PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

NCT01131247 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

37

Enrollment

OTHER

Sponsor class

Stopped PI left institution

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG: ofatumumab + bendamustine

Sponsor

Nevada Cancer Institute

Collaborators

[object Object]
[object Object]